More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...